ACRIVON THERAPEUTICS INC

Company Overview

Acrivon Therapeutics Inc (Healthcare; Biotechnology) is a clinical-stage precision oncology company developing targeted therapeutics paired with proteomics-based companion diagnostics through its AP3 Generative Phosphoproteomics platform and OncoSignature assays. Lead programs include ACR-1368 (prexasertib, in a registrational-intent Phase 2 master protocol in endometrial cancer using an OncoSignature for patient selection) and ACR-2316 (dual WEE1/PKMYT1 inhibitor in Phase 1), with R&D concentrated in Watertown, MA and Lund, Sweden. The company is small and R&D-intensive (≈75 FTEs, ~64 in R&D), outsources GMP manufacturing to CMOs, relies on a Lilly in-license for ACR-1368, and has Breakthrough Device and Fast Track designations for its diagnostic/drug pairing. Recent financials show widening losses driven by higher clinical spend, a cash runway management focus (management projects funding into 2027), and dependence on financing, milestones and successful trial enrollment.

Executive Compensation Practices

Compensation at Acrivon is likely weighted toward equity and milestone-contingent pay given heavy R&D burn, limited product revenue, and explicit increases in stock-based compensation reported in G&A. Management incentives are expected to be driven by clinical and regulatory milestones (e.g., positive ACR-1368 readouts, OncoSignature validation, Phase 2B initiations, FDA interactions), enrollment and target engagement metrics for ACR-2316, plus licensing/collaboration outcomes (Lilly milestones, Akoya diagnostic milestones) that materially affect cash needs. The company’s use of Black–Scholes inputs and guideline peers for volatility in stock‑based compensation valuation highlights sensitivity of reported pay expense to market volatility and peer selection — a factor investors should watch when comparing pay levels. Given runway and capital-raising risk, boards in similar biotech firms often favor equity-heavy grants, time- and performance-based vesting, and potential bonus triggers tied to financings or partnering events to conserve cash.

Insider Trading Considerations

Insider transactions at Acrivon will likely cluster around clinical/data milestones, regulatory filings and partner announcements (e.g., Breakthrough Device/Fast Track news, OncoSignature validation, Phase 2/Phase 1 data updates) and around financings (PIPEs or secondary offerings) that dilute equity — these are high-impact events for an early-stage biotech. Expect insiders to use stock-based grants and option exercises for liquidity or tax planning; look for Form 4 activity tied to option exercises, subsequent sales, and any 10b5-1 trading plans announced to provide pre-arranged sale windows. Regulatory and contractual constraints are material: trading must avoid material nonpublic information (trial outcomes, enrollment stoppages), collaboration/license agreements (Lilly/Akoya) can impose transfer/lock-up terms, and the SEC’s insider-reporting rules and company blackout windows are particularly relevant for a firm with frequent, market-moving clinical updates.